Sugi Predict

Sugi Predict / Compounds / SCHEMBL62801

SCHEMBL62801

SCHEMBL62801

O=C1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ CYP2D6 P10635 2/20 0.50
▸ OPRM1 P35372 2/20 0.50
▸ CHRM2 P08172 1/20 0.50
▸ CHRM4 P08173 1/20 0.50
▸ CHRM5 P08912 1/20 0.50
▸ ADRA2A P08913 1/20 0.50
▸ ADORA3 P0DMS8 1/20 0.50
▸ CHRM1 P11229 1/20 0.50
▸ CHRM3 P20309 1/20 0.50
▸ DRD1 P21728 1/20 0.50
▸ ADRA1D P25100 1/20 0.50
▸ HTR2A P28223 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ HRH1 P35367 1/20 0.50
▸ DRD3 P35462 1/20 0.50
▸ HTR2B P41595 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11616979 0.81 KMT2A (0.50) KMT2AMEN1CYP2D6OPRM1CHRM2
SCHEMBL22778500 0.81 CYP2D6 (0.46) KMT2AMEN1CYP2D6OPRM1CHRM2
SCHEMBL1500553 0.78 CYP2D6 (0.53) KMT2AMEN1CYP2D6OPRM1CHRM2
SCHEMBL5391913 0.78 KMT2A (0.57) KMT2AMEN1CYP2D6OPRM1CHRM2
SCHEMBL4067076 0.77 KMT2A (0.50) KMT2AMEN1CYP2D6OPRM1CHRM2
SCHEMBL27750604 0.77 OPRM1 (0.50) KMT2AMEN1CYP2D6OPRM1CHRM2
SCHEMBL14865240 0.77 ALDH1A1 (0.33) KMT2AMEN1CYP2D6OPRM1CHRM2
Bromide SCHEMBL3300210 0.77 CYP2D6 (0.52) KMT2AMEN1CYP2D6OPRM1CHRM2
SCHEMBL3298020 0.77 OPRM1 (0.46) CYP2D6OPRM1ALDH1A1OPRD1OPRK1
SCHEMBL8175607 0.75 OPRM1 (0.78) KMT2AMEN1CYP2D6OPRM1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 856 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115650893-B Synthesis method of 1-benzhydryl azetidine-3-one 南通华祥医药科技有限公司 2024-08-06 — — CN claimed
CN-115650893-A Synthesis method of 1-benzhydrylazetidin-3-one 南通华祥医药科技有限公司 2023-01-31 — — CN claimed
EP-2683723-B1 SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS ZOETIS SERVICES LLC (US) 2016-05-25 — — EP claimed
EP-2683723-A1 SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS Zoetis LLC (US) 2014-01-15 — — EP claimed
US-8466115-B2 Spirocyclic isoxazoline derivatives as antiparasitic agents ZOETIS LLC (US) 2013-06-18 — — US claimed
WO-2012120399-A1 SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-09-13 — — WO claimed
US-20120232026-A1 SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-09-13 — — US claimed
CN-122079847-A Key intermediate of 3-hydroxymethyl azetidine-1-carboxylic acid tert-butyl ester and preparation method thereof — 2026-05-26 — — CN disclosed
CN-122079847-A Key intermediate of 3-hydroxymethyl azetidine-1-carboxylic acid tert-butyl ester and preparation method thereof — 2026-05-26 — — CN disclosed
US-20260035356-A1 MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2026-02-05 — — US disclosed
US-20250368666-A1 INDAZOLE COMPOUNDS TYRA BIOSCIENCES INC (US) 2025-12-04 — — US disclosed
US-20250276976-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-09-04 — — US disclosed
US-20250276983-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 IAMBIC THERAPEUTICS, INC. 2025-09-04 — — US disclosed
WO-1994002477-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1994-02-03 — — WO disclosed
US-5281585-A Secondary amide containing antagonist MERCK & CO., INC. (US) 1994-01-25 — — US disclosed
WO-1993018029-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1993-09-16 — — WO disclosed
EP-0529702-A1 Dihydropyridine derivatives, their preparation and their use Sankyo Company Limited (JP) 1993-03-03 — — EP disclosed
US-5073646-A Chemical intermediates, microbiocides LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 1991-12-17 — — US disclosed
US-4772596-A CALCIUM BLOCKERS SANKYO COMPANY LIMITED (JP) 1988-09-20 — — US disclosed
EP-0266922-A1 Dihydropyridine derivatives, their preparation and their use Sankyo Company Limited (JP) 1988-05-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276976-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, MYLK2, TNNT2 KMT2A 2173/4885MEN1 3423/4885CYP2D6 3802/4885
US-20120232026-A1 SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS REN, AVPR1A, AVPR1B KMT2A 2934/4885MEN1 2227/4885CYP2D6 142/4885
US-20260035356-A1 MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE TYK2, CRBN, CSNK2A3 KMT2A 640/4885MEN1 3018/4885CYP2D6 3888/4885
US-20250368666-A1 INDAZOLE COMPOUNDS FGFR1, FGFR3, FGFR2 KMT2A 2751/4885MEN1 3235/4885CYP2D6 2312/4885
US-20250276983-A1 COMPOUNDS AND METHODS FOR MODULATING HER2 ERBB2, EGFR, ERBB3 KMT2A 978/4885MEN1 736/4885CYP2D6 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.